0001437749-26-016721
SEC filingQ3 FY2026 delivered challenging results with revenue down 33% to $12.4M from Pediatric Portfolio declines due to returns and higher rebates, partially offset by EXXUA launch, swinging to operating loss of $4.1M and net loss of $5.6M despite gross margin resilience at 61.2%.
Aytu BioPharma's Q3 FY2026 results reflect a strategic pivot toward EXXUA commercialization amid legacy Pediatric Portfolio headwinds. Revenue of $12.4 million declined 32.7% year-over-year from $18.5 million, primarily because the Pediatric Portfolio suffered from elevated returns during the quarter and unfavorable payer mix leading to higher rebates. These pressures were partially offset by EXXUA's successful launch in Q2 FY2026, which contributed incremental net revenue as the centerpiece of commercial efforts.
Gross profit of $7.6 million decreased 40.7% from $12.8 million, yet the gross margin remained robust at 61.2%. This resilience underscores effective cost management at the gross level despite the revenue contraction and shifting product mix away from higher-margin legacy items toward the new EXXUA franchise.
Operating income flipped to a $4.1 million loss from a $2.4 million profit, with operating margin at -32.7%. Selling and marketing expenses rose, driven by labor, service costs, and EXXUA launch investments, reflecting the ramp in promotional activities to establish market presence for this key growth driver.
Net income swung to a $5.6 million loss from $4.0 million profit, with diluted EPS at -$0.53 versus $0.21. This deterioration stems from the operating shortfall compounded by non-operating volatility, particularly fair value changes in derivative warrant liabilities revalued each period using Black-Scholes or Monte Carlo models. Unlike prior year gains from falling stock prices, current period losses arose from rising equity values.
Cash flow from operations improved markedly to -$1.1 million used from -$4.7 million, with free cash flow at -$1.1 million after minimal $17 thousand capex. This progress indicates stabilizing working capital dynamics during the portfolio transition.